Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-01-17

FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for ADEMPAS (riociguat) from Bayer HealthCare Pharmaceuticals Inc., approving a change to the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Adempas (riociguat)

Snippet

SUPPL AP for ADEMPAS (RIOCIGUAT)